# Glycemic Control and Treatment Satisfaction Using Finesse Versus Pen for Initiating Bolus Insulin Dosing in Type 2 Diabetes Patients

Study · id `cardio:ct-nct02542631` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02542631](<https://clinicaltrials.gov/study/NCT02542631>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02542631

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 278 participants.

## Technical summary

Registry record NCT02542631. Randomized; no masking; primary purpose treatment. Start 2015-08-01 (actual); primary completion 2017-08-31 (actual). Results posted on 2018-11-07.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 278 participants (enrolled count; ClinicalTrials.gov record NCT02542631, source copy `cardio:ctgov-nct02542631-2025-02-04`, retrieved 2026-10-26)
- Started: 2015-08-01 (actual) (ClinicalTrials.gov record NCT02542631, source copy `cardio:ctgov-nct02542631-2025-02-04`, retrieved 2026-10-26)
- Primary completion: 2017-08-31 (actual) (ClinicalTrials.gov record NCT02542631, source copy `cardio:ctgov-nct02542631-2025-02-04`, retrieved 2026-10-26)
- Completion: 2017-08-31 (actual) (ClinicalTrials.gov record NCT02542631, source copy `cardio:ctgov-nct02542631-2025-02-04`, retrieved 2026-10-26)
- Results first posted: 2018-11-07 (ClinicalTrials.gov record NCT02542631, source copy `cardio:ctgov-nct02542631-2025-02-04`, retrieved 2026-10-26)
- Countries: United States; France; Germany; United Kingdom (ClinicalTrials.gov record NCT02542631, source copy `cardio:ctgov-nct02542631-2025-02-04`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02542631-2025-02-04`, retrieved 2026-10-26)

## The registry's words

- Brief title: Glycemic Control and Treatment Satisfaction Using Finesse Versus Pen for Initiating Bolus Insulin Dosing in Type 2 Diabetes Patients
- Condition: Diabetes Mellitus, Type 2
- Intervention (Device): Bolus Insulin Patch (Calibra Finesse)
- Intervention (Device): Insulin Pen (Novo-Nordisk FlexPen®)
- Lead sponsor: Calibra Medical, Inc.
- Lead sponsor class: INDUSTRY
- Collaborator: Medpace, Inc.
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as a collaborator: Medpace, Inc. (`cardio:org-medpace-inc`)

## Provenance

Content hash: c9697d38aedfa9cd17dd78300b85dcade920aa64d9d99080a579eae0308506e4
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
